(1 - 26 von 29
)
'Promising' superbug treatments | The Timeswww.thetimes.co.uk › article
www.thetimes.co.uk
Dr Miroslav Ravic, chief executive officer of MGB Biopharma, said: “We are very excited that MGB BP-3 shows such a promising response ...
New C.diff drug to be tested on patients for first time - BBC News
www.bbc.co.uk
Chief executive Dr Miroslav Ravic said: "We are already witnessing renewed interest in our new anti-bacterial agent and its trial in key medical ...
Glasgow firm raises cash for Clostridium difficile battle |...
www.heraldscotland.com
A NOVEL antibiotic, developed in Scotland to combat Clostridium difficile, is a step closer to market following a £920,000 fundraising by…
New C.diff drug to be tested on patients for first time - BBC Newswww.bbc.com › news › uk-scotlan...
www.bbc.com
Chief executive Dr Miroslav Ravic said: "We are already witnessing renewed interest in our new anti-bacterial agent and its trial in key medical centres in North ...
Biopharm firm tackling antibiotic resistance closes funding roundwww.scotsman.com › business › bi...
www.scotsman.com
MGB Biopharma chief executive Miroslav Ravic MGB Biopharma boss Miroslav Ravic said investors “have demonstrated their confidence in ...
Grant Brings New Groove to Anti-Infective Developer
www.genengnews.com
MGB Biopharma wins $2.2M from UK agency toward Phase I trial of oral MGB-BP-3 for Clostridium difficile
Antimicrobial resistance affects everyone - come and join the...
amr.dundee.ac.uk
Dr Camilla Wiuff, Strategic Lead, Microbiology at Health Protection Scotland Dr. Miroslav Ravic, Chief Executive Officer, Chief Science Officer ...
Life sciences firm makes breakthrough in anti-superbug testingwww.insider.co.uk › News
www.insider.co.uk
Dr Miroslav Ravic, chief executive officer of MGB Biopharma, said: “We are delighted to have completed the first of three patient cohorts in our ...
FDA Grants QIDP Designation to MGB-BP-3 to Treat Clostridium...
www.contagionlive.com
The CEO of MGB Biopharma, Miroslav Ravic, MD, PhD, said, “We are very pleased with the FDA's decision to grant QIDP designation to ...
MGB Biopharma Announces Promising Phase IIa Clinical Trial Update for...
www.finanzen.ch
GLASGOW, Scotland, Oct. 10, PRNewswire/ -- MGB Biopharma, a bio… company developing a novel class of anti-infectives to address...
MGB Biopharma Closes $1 million Financing Round to Finance...
www.scottishlifesciencesassociation.org.uk
News
MGB Biopharma Continues to Progress its Truly Novel Anti ...www.technologynetworks.com › m...
www.technologynetworks.com
“MGB Biopharma has made excellent progress across all areas of the business in 2014,” said Dr Miroslav Ravic, MGB Biopharma's CEO.
MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3...
www.prnewswire.co.uk
Miroslav Ravic, CEO of MGB Biopharma, said: "The development of this new IV formulation is a fantastic breakthrough for MGB. I would like to ...
MGB Biopharma and Almac collaborate on contract manufacturing project
www.manufacturingchemist.com
Dr Miroslav Ravic, ceo of MGB Biopharma, said: 'Almac has already shown an intuitive understanding of what it takes to support a small ...
MGB Biopharma Successfully Completes Phase I Clinical Trial with Oral...
www.technologynetworks.com
Technology Networks is an internationally recognised publisher that provides access to the latest scientific news, products, research, videos and posters.
MGB Biopharma awarded £2.78m grant for Phase IIa trial - Young...
www.ycfscotland.co.uk
Dr Miroslav Ravic, CEO of MGB Biopharma, said “We are delighted that MGB Biopharma has been chosen as one of the recipients of this ...
MGB Biopharma reveals positive mid-stage diarrhoea data ...www.pharmatimes.com › news
www.pharmatimes.com
Dr Miroslav Ravic, chief executive officer of MGB Biopharma, said: “We are delighted to have completed the first of three patient cohorts in our ...
MGB Biopharma spun out of Strathclyde with £2M to develop antibiotics...
sciencebusiness.net
Spin outMGB BioPharma has been spun out of Strathclyde University in Glasgow to commer…e antibacterial technology. The company, which is being run by...
Maker of new C.diff drug in talks with FDA | The Nationalwww.thenational.scot › business
www.thenational.scot
Dr Miroslav Ravic, CEO of MGB Biopharma, said: “Our talks with the FDA have provided clear guidelines on the development path we need to ...
MGB Biopharma drug secures £4m funding | The Scotsman
www.scotsman.com
An anti-bacterial drug developed in Scotland to combat infections is entering the next phase of clinical trials after receiving a total £4 million investment.
MGB Biopharma secures £1.3m funding to test C.difficile drug in...
www.insider.co.uk
Edinburgh-based angel investor Archangels and Scottish Investment Bank among investors which also includes Syndicate Room for the first time
New funding to support global fight against C. difficile - MBM ...mbmcommercial.co.uk › News
mbmcommercial.co.uk
Dr Miroslav Ravic, CEO and CMO of MGB Biopharma, said: “MGB Biopharma now has the funds with which to initiate our Phase IIa study in ...
MGB Biopharma raises £920,000 to take anti-infectives to clinical...
www.insider.co.uk
Glasgow-based life sciences company closes funding round aimed at helping it develop drugs to combat antibiotic resistance
Pharma group receives £920k injection | The Scotsman
www.scotsman.com
An antibiotic which has been developed in Scotland for the treatment of Clostridium difficile, or C. diff, has moved a step closer to being brought to market...
Scottish Investment Bank supports the development of a new drug to...
www.scottish-enterprise-mediacentre.com
Dr Miroslav Ravic, CEO of MGB Biopharma, said: “The danger posed by antimicrobial resistance to global public health is immense. Without ...
sortiert nach Relevanz / Datum